Drug Profile
Research programme: cancer DNA vaccine - Mologen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mologen
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lymphoblastic-leukaemia in Germany (Parenteral)
- 08 Dec 2009 Preclinical trials in Acute lymphoblastic leukaemia in Germany (Parenteral)